Targeting a large potential market with unmet medical need

  • Global sales of over the counter topical analgesics  US$ 4.9 billion1.
  • February 2020 - Approval in the US of GSK’s Voltaren Arthritis Pain Gel over the counter opening up a new OTC market opportunity.
  • Demand for safe, effective and long lasting topical pain relief. Topical treatments are first line of treatment for osteoarthritis of the joints.
  • DermaSys® provides faster drug permeation, a key point of difference. 

Topical NSAIDS treatments are recommended by the National Institute for Health and Care Excellence (NICE) as the first line treatment for joint pain associated with osteoarthritis, in preference to oral NSAIDs, owing to concerns over systemic side effects caused by the long term use of oral NSAIDs.

Commercial strategy

TPR100 is partnered for manufacturing and distribution in the UK with Thornton & Ross, one of the UK’s largest consumer healthcare companies and a subsidiary of STADA AG. In February 2019, the UK Medicines and Healthcare products Regulatory Agency (MHRA) responded to Thornton & Ross’s marketing authorisation application filed in July 2018, with a number of questions requiring additional laboratory work specifically around the permeation characteristics of TPR100 to be conducted. This further laboratory work is now complete.  In conjunction with its commercial partner, Futura is seeking a scientific advisory meeting with the MHRA before the end of 2020 to review the data  and provide regulatory clarity around the exact pathway for approval and any outstanding additional requirements. Futura is awaiting regulatory authorisation in the UK before progressing further with licensing discussions for further regions. 

  1. Mid year to 2017, Nicholas Hall ‘s OTC Reports,  Analgesics The Evolving Self-Care market for pain relief